No products in the cart.
Pre-made Denintuzumab benchmark antibody ( Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-139
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Denintuzumab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Denintuzumab mafodotin (INN; development codes SGN-19A or SGN-CD19A) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
| Products Name (INN Index) | Pre-Made Denintuzumab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody |
|---|---|
| INN Name | Denintuzumab |
| Target | CD19 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Seattle Genetics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Diffuse large B cell lymphoma,Follicular lymphoma,Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD19 |
| Package |
Previous slide
Next slide
